^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    THIO

    i
    Other names: THIO, 6-thio-dG, 6-thio-2′-Deoxyguanosine
    Associations

    News

    Trials
    Company:
    MAIA Biotech
    Drug class:
    Telomerase inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    THIO-101: THIO Sequenced with Cemiplimab in Advanced NSCLC (clinicaltrials.gov)
    P2, N=182, Active, not recruiting, Maia Biotechnology | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Oct 2026 | Trial primary completion date: Jun 2024 --> Aug 2025
    Enrollment closed • Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    IL6 (Interleukin 6) • CRP (C-reactive protein)
    |
    Libtayo (cemiplimab-rwlc) • THIO
    over1year
    Activating an Adaptive Immune Response with a Telomerase-mediated Telomere Targeting Therapeutic in Hepatocellular Carcinoma. (PubMed, Mol Cancer Ther)
    Importantly, the extracellular HMGB1 (high-mobility group box 1) protein acts as a prototypical endogenous DAMP (Damage Associated Molecular Pattern) in eliciting adaptive immunity by THIO. These results provide a strong rationale for combining telomere-targeted therapy with immunotherapy.
    Journal
    |
    HMGB1 (High Mobility Group Box 1)
    |
    THIO